Wikipedia -WSS

Wikipedia

author：knowledge 2025-09-30 15:15:10 - browse：9

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Sickle cell gene therapy cures need to be accessible in Africa

leisure time

knowledge

leisure time

WSS

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Antibody drugs appear effective. Now can we make enough of them?

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

CDC marks new Covid

A Greenpeace activist is fined for crash

Antibody drugs appear effective. Now can we make enough of them?

knowledge

Wikipedia

leisure time

Psychedelics group wrestles with new pharma identity

The drug industry has found itself all alone in Washington

United colonoscopy coverage change 'may cost lives,' doctors say

With psoriasis trial ahead, Alumis raises $259 million

Duchenne breakthrough therapy leaves behind pioneering families

RSV shot was 90% effective at preventing hospitalizations in kids

DIEP, the 'gold standard' of breast reconstruction, is under threat

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

Apple is now the first public company to be valued at $3 trillion

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Wikipedia

The debate over Covid

NEJM study link tiny plastics in blood vessels to heart problems

Sickle cell gene therapy cures need to be accessible in Africa

First medicine developed to treat MASH expected to be approved soon

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup

leisure time

knowledge

leisure time

hotspot